Sandbox: HAR

COVID-19 Microchapters

Home

Long COVID

Frequently Asked Outpatient Questions

Frequently Asked Inpatient Questions

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating COVID-19 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Vaccines

Secondary Prevention

Future or Investigational Therapies

Ongoing Clinical Trials

Case Studies

Case #1

Sandbox: HAR On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sandbox: HAR

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sandbox: HAR

CDC on Sandbox: HAR

Sandbox: HAR in the news

Blogs on Sandbox: HAR

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Sandbox: HAR

For COVID-19 frequently asked inpatient questions, click here

For COVID-19 frequently asked outpatient questions, click here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Harmeet Kharoud M.D.[2]

Synonyms and keywords: Multisystem Inflammatory Syndrome in Children (MIS-C)

## Overview

[edit | edit source]

Multisystem Inflammatory Syndrome in Children (MIS-C) is a condition that causes inflammation of some parts of the body like heart, blood vessels, kidneys, digestive system, brain, skin, or eyes. According to recent evidence, it is suggested that children with MIS-C had antibodies against COVID-19 suggesting children had COVID-19 infection in the past. This syndrome appears to be similar in presentation to Kawasaki disease, hence also called Kawasaki -like a disease. It also shares features with staphylococcal and streptococcal toxic shock syndromes, bacterial sepsis, and macrophage activation syndromes.[1]

## Classification of Disease Severity of MIS-C

[edit | edit source]

* Mild Disease
* Children with MIS-C fall under this category who-[2]
* require minimal to no respiratory support.
* minimal to no organ injury
* normotensive
* Do not meet the criteria for ICU admission.
* Severe Disease
* Children with MIS-C fall under this category who-[2]
* have significant oxygen requirements (HFNC, BiPAP, mechanical ventilation).
* have a mild-severe organ injury and ventricular dysfunction.
* have a vasoactive requirement.
* meet the criteria for ICU admissions

## Pathophysiology

[edit | edit source]

* The excat pathophysiological mechanism of MIS-C is unclear. Since there is a lag time between MIS-C appearance and COVID-19 infection it is suspected to be causing by antibody dependent enhancement.[3]
* Another hypothesis is that since coronavirus block type1 and type III interferons, it results in delayed cytokine response in children with initially high viral load or whose immune response is unable to control infections causing MIS-C. Therefore, IFN responses result in viral clearance when the viral load is low resulting in mild infection. However, when the viral load is high and /or immune system is not able to clear the virus, the cytokine storm result in multisystem inflammatory syndrome in children (MIS-C).[3]
* It is also suspected that since MIS-C presents predominantly with gastrointestinal manifestations, it replicates predominantly in the gastrointestinal tract.[3]

## Differentiating Any Disease from other disease

[edit | edit source]

It should be differentiated from following diseases

* Bacterial sepsis
* Staphylococcal and streptococcal toxic shock syndrome
* Kawasaki disease.
* More information about the differential diagnosis could be found here.

## Epidemiology and Demographics

[edit | edit source]

* According to a recent study among the 186 children with MIS-C, the rate of hospitalization was 12% between March 16 and April 15 and 88% between April 16 and May 20.
* 80% of the children were admitted to the intensive care unit and 20% of the children required mechanical ventilation.[4]
* 4% of the children required extracorporeal membrane oxygenation.[4]
* The mortality rate among 186 children with MIS-C was 2%.[4]

Age

* Among the 186 children with MIS-C distribution of age group was[4]
* <1yr-7%
* 1-4yr-28%
* 5-9yr-25%
* 10-14yr-24%
* 15-20yr-16%.

Gender

* Among the 186 children with MIS-C

Comorbidities

* Children with MIS-C had following underlying comorbidities.[4]
* Clinically diagnosed Obesity-8%
* BMI-Based Obesity-29%
* Cardiovascular diasease-3%
* Respiratory disease-18%
* Autoimmune disease or immunocompromising condition-5%

Organ System Involved

* 71% of children had involvement of at least four organ systems.[4]

The most common organ system involved in MIS-C children among a total of 186 children were.[4]

* Gastrointestinal(92%)
* Cardiovascular(80%)
* Hematologic(76%)
* Mucocutaneous(74%)
* Pulmonary(70%)
* Historical perspective

## Complications and Prognosis

[edit | edit source]

### Complications

[edit | edit source]

* Severe myocardial infarction[4]
* Cardiac failure/arrest[4]
* ARDS[4]
* Hypervolemia[4]
* Acute Kidney Injury
* Peritonitis[4]
* Thrombotic complications.[4]

## Diagnosis

[edit | edit source]

### Diagnostic Criteria

[edit | edit source]

##### Preliminary WHO case definition: Children and adolescents

[edit | edit source]

* 0–19 years of age with fever >3 days[5]

AND

* Two of the following:

1. Rash or bilateral non-purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands or feet)
2. Hypotension or shock
3. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP)
4. Evidence of coagulopathy (by PT, PTT, elevated D-Dimers)
5. Acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain)

AND

* Elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin

AND

* No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes

AND

* Evidence of COVID-19 (RT-PCR, antigen test or serology-positive), or likely contact with patients with COVID-19

##### CDC Case Definition for MIS-C

[edit | edit source]

* An individual aged <21 years presenting with fever, laboratory evidence of inflammation**, and evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological);[6]

AND

No alternative plausible diagnoses;

AND

Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or exposure to a suspected or confirmed COVID-19 case within the 4 weeks prior to the onset of symptoms.

### Signs and Symptoms

[edit | edit source]

* Fever lasting 24 hours or longer.[1]
* Vomiting[1]
* Diarrhea[1]
* Abdominal pain[1]
* Skin rash[1]
* Conjuctivitis[1]
* High ESR[1]
* Redness or swelling of the lips and tongue[1]
* Lethargy[1]
* Redness or swelling of the hands or feet[1]
* Confusion[1]
* Headache[1]
* Sore throat[1]
* Syncope[1]
* Lymphadenopathy[1]

Emergency Warning Signs

* Difficulty Breathing[1]
* Chest pain
* New onset confusion
* Lethargy
* Cyanosis
* Abdominal pain

### Physical Examination

[edit | edit source]

Blood Investigations

* Lymphopenia, Neutrophilia, Anemia, Thrombocytopenia have been seen in MIS-C pateints. Abnormal fibrinogen, Hypoalbuminaemia, elevated creatiine kinase (CK), LDH, triglycerides have been observed in MIS-C patients.[1]

#### Inflammatory biomarkers

[edit | edit source]

Elevation of inflammatory markers including ESR, C reactive protein and procalcitonin are usually seen in MIS-C. Increased level of Interleukin-6 (IL-6), Interleukin-10(IL-10) d-dimer, serum ferritin, prothrombin time have also been seen in MIS-C.[1]

#### Cardiac biomarkers

[edit | edit source]

Elevation of cardic enzymes including cardiac troponins (cardiac troponin I(cTnI) and cardiac troponin T (cTnT)) and Brain natriuretic peptide (BNP)) has been observed in MIS-C patients.[1]

### Radiological Findings

[edit | edit source]

* Following Radiological Findings are observed in MIS-C patients.[1]

Test  | Findings

|

Chest Xray | patchy symmetrical infiltrates, pleural effusion
Echocardiogram and EKG | myocarditis, valvulitis, pericardial effusion, coronary artery dilatation
Abdominal USG | colitis, ileitis, lymphadenopathy, ascites, hepatosplenomegaly

Blood Culture, Viral PCR

* Absence of other potential causative organisms. IgG levels and IgM levels of SARS-CoV-2 are detected.

## Treatment

[edit | edit source]

### Medical Therapy

[edit | edit source]

* All the children with MIS-C are treated as suspected COVID-19.
* Mild to Moderate cases of MIS-C are managed supportively.[7][8]
* Supplemental oxygen is required in children with low oxygen saturation.[8]
* Fluid resuscitation in 10 ml/kg aliquots with reevaluation after each bolus. Maintain euvolemia. Avoid hypervolemia.[8]
* Anti-inflammatory treatments with Intravenous immunoglobulin(IVIG) with or without corticosteroids have shown a good response rate.[7][8]
* Aspirin has been used primarily for its antiplatelet effect. It is recommended in all patients with MIS-C.[7][8]
* Anakinra is considered if fevers last more than 24 hours post steroids/IVIG or in the moderate or severe presentation.[7][8]
* Tocilizumab is also considered if fevers last more than 24 hours post steroids/IVIG or in the moderate or severe presentation.[7][8]
* Empiric antibiotics like vancomycin, ceftriaxone, and clindamycin are given for community-acquired shock presentation until cultures are negative for 48 hours.[7][8]

Presentation  | Treatment

|

Mild Disease |

* Symptomatic Treatment

Severe Disease |

* Symptomatic Treatment
* IVIG(IV)
* Corticosteroids(IV/PO)
* Consider adding Anakinra or Tocilizumab if fever persist for more than 24 hours post steroids and IVIG use.

## Prevention of MIS-C

[edit | edit source]

* MIS-C can be prevented by reducing the risk of child exposure to COVID-19 infection.

## References

[edit | edit source]

1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 "Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19" (PDF). line feed character in `|title=` at position 46 (help)
2. ↑ 2.0 2.1 "Evaluation and Management of COVID-19 Multisystem Inflammatory Syndrome in Children (MIS-C)" (PDF). line feed character in `|title=` at position 63 (help)
3. ↑ 3.0 3.1 3.2 Rowley, Anne H. (2020). "Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children". Nature Reviews Immunology. doi:10.1038/s41577-020-0367-5. ISSN 1474-1733.
4. ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 Feldstein, Leora R.; Rose, Erica B.; Horwitz, Steven M.; Collins, Jennifer P.; Newhams, Margaret M.; Son, Mary Beth F.; Newburger, Jane W.; Kleinman, Lawrence C.; Heidemann, Sabrina M.; Martin, Amarilis A.; Singh, Aalok R.; Li, Simon; Tarquinio, Keiko M.; Jaggi, Preeti; Oster, Matthew E.; Zackai, Sheemon P.; Gillen, Jennifer; Ratner, Adam J.; Walsh, Rowan F.; Fitzgerald, Julie C.; Keenaghan, Michael A.; Alharash, Hussam; Doymaz, Sule; Clouser, Katharine N.; Giuliano, John S.; Gupta, Anjali; Parker, Robert M.; Maddux, Aline B.; Havalad, Vinod; Ramsingh, Stacy; Bukulmez, Hulya; Bradford, Tamara T.; Smith, Lincoln S.; Tenforde, Mark W.; Carroll, Christopher L.; Riggs, Becky J.; Gertz, Shira J.; Daube, Ariel; Lansell, Amanda; Coronado Munoz, Alvaro; Hobbs, Charlotte V.; Marohn, Kimberly L.; Halasa, Natasha B.; Patel, Manish M.; Randolph, Adrienne G. (2020). "Multisystem Inflammatory Syndrome in U.S. Children and Adolescents". New England Journal of Medicine. doi:10.1056/NEJMoa2021680. ISSN 0028-4793.
5. ↑ "Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19".
6. ↑ "CDC case definationlast=".
7. ↑ 7.0 7.1 7.2 7.3 7.4 7.5 "Emergency Department, ICU and Inpatient Clinical Pathway for Evaluation of Possible Multisystem Inflammatory Syndrome (MIS-C)". line feed character in `|title=` at position 61 (help)
8. ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 "Evaluation and Management of COVID-19 Multisystem Inflammatory Syndrome in Children (MIS-C)" (PDF). line feed character in `|title=` at position 63 (help)

## References

[edit | edit source]

## Presentations

[edit | edit source]

* Presentation of COVID-19 is less severe in children as compared to adults. Most of the children are asymptomatic.[1]
* According to CDC, as of April 2, 2020, 1.7% confirmed cases of COVID-19 were reported in children aged <18 years age among the total number of confirmed cases of COVID-19.
* COVID-19 in children could range from asymptomatic presentation to mild to severe disease.
* The incubation period of SARS-CoV-2 varies from 2 to 14 days with most patients developing symptoms 3 to 7 days after exposure.[1]

Symptoms

* Fever and Cough are one of the most common symptoms reported in children. One study showed fever is prevalent in 47.5% of children and cough in 41.5% among the 1124 children with COVID-19. According to the CDC, fever, and cough was reported in 56% and 54% of children with COVID 19
* Dyspnea, nasal congestion, pharyngeal erythema, and sore throat are also common presentations in children.
* Gastrointestinal symptoms-The gastrointestinal manifestation in COVID-19 positive children are diarrhea, vomiting, abdominal pain, nausea, and anorexia. Children can present with gastrointestinal symptoms in the absence of respiratory symptoms.
* Cutaneous Findings\- The cutaneous findings in COVID-19 positive children range from petechiae to papulovesicular rashes to diffuse urticaria. These appear early in the course of COVID-19 and result secondary to viral replication or circulating cytokines. Many patients with COVID-19 are presenting with chilblains like lesions unrelated to cold. Chilblains are painful or itchy swellings of the toes and fingers, caused by small-vessel inflammation from repeated exposure to cold. A retrospective case series presented 22 children and adolescents with COVID-19 who presented with chillblains lesions. [2][3]
* Neurological manifestation\- The presentation of neurological manifestation in children is rare. However, a case report described a rare case of a 6-week old infant with COVID-19 who had 10-15 seconds episodes of upward gaze and bilateral leg stiffening.[4]

* Neonates and Infants with COVID-19 are often asymptomatic or present with fever with or without mild cough and congestion.

Severity of Disease in Children with COVID-19

* Asymptomatic presentation\-
* A large number of children with COVID-19 are asymptomatic.
* According to one study 14.2% of children were asymptomatic. Another study showed 18% of asymptomatic children with COVID-19.
* Mild Disease
* Few numbers of children also present with mild manifestations of COVID-19.
* A study showed 36.3% of children present with a mild form of the disease.

Moderate

*     *   * Severe
* 2.1% of children present with a severe form of COVID-19 disease.
* Children with underlying comorbidities are more susceptible to getting severe COVID-19 disease.

===Complication 1===[5]

### Multisystem Inflammatory Syndrome in Children (MIS-C)

[edit | edit source]

* It is a condition that causes inflammation of some parts of the body like heart, blood vessels, kidneys, digestive system, brain, skin, or eyes.
* According to recent evidence, it is suggested that children with MISC had antibodies against COVID-19 suggesting children had COVID-19 infection in the past.
* This syndrome appears to be similar in presentation to Kawasaki disease, hence also called Kawasaki -like a disease. It also shares features with staphylococcal and streptococcal toxic shock syndromes, bacterial sepsis, and macrophage activation syndromes. "www.rcpch.ac.uk" (PDF).

Epidemiology and Demographics

* According to a recent study among the 186 children with MIS-C, the rate of hospitalization was 12% between March 16 and April 15 and 88% between April 16 and May 20.
* 80% of the children were admitted to the intensive care unit and 20% of the children required mechanical ventilation.
* 4% of the children required extracorporeal membrane oxygenation.
* The mortality rate among 186 children with MIS-C was 2%.

Age

* Among the 186 children with MIS-C distribution of age group was
* <1yr-7%
* 1-4yr-28%
* 5-9yr-25%
* 10-14yr-24%
* 15-20yr-16%.

Gender

* Among the 186 children with MIS-C

Comorbidities

* Children with MIS-C had following underlying comorbidities.
* Clinically diagnosed Obesity-8%
* BMI-Based Obesity-29%
* Cardiovascular diasease-3%
* Respiratory disease-18%
* Autoimmune disease or immunocompromising condition-5%

Organ System Involved

* 71% of children had involvement of at least four organ systems.

The most common organ system involved in MIS-C children among a total of 183 children were.

* Gastrointestinal(92%)
* Cardiovascular(80%)
* Hematologic(76%)
* Mucocutaneous(74%)
* Pulmonary(70%).

Pathophysiology

* Exact cause of MIS-C is unclear. It is suspected that it is caused by a delayed immune response to the SARS-CoV-2, causing inflammation of organs."Multisystem Inflammatory Syndrome in Children (MIS-C) | Boston Children's Hospital".
* It is also suspected that it is occurring due to antibody-mediated reaction."Multisystem Inflammatory Syndrome in Children (MIS-C) | Boston Children's Hospital".

Symptoms"www.rcpch.ac.uk" (PDF).

* Fever lasting 24 hours or longer(78%)
* Vomiting
* Diarrhea
* Abdominal pain
* Skin rash
* Conjuctivitis
* Redness or swelling of the lips and tongue
* Lethargy
* Redness or swelling of the hands or feet
* Confusion
* Headache
* Sore throat
* Syncope
* Lymphadenopath

Emergency Warning Signs

* Difficulty Breathing
* Chest pain
* New onset confusion
* Lethargy
* Cyanosis
* Abdominal pain

Laboratory Findings"www.rcpch.ac.uk" (PDF).

* Abnormal fibrinogen
* High CRP
* High D Dimer
* High Ferritin
* Hypoalbuminaemia
* Lymphopenia
* Neutrophilia
* Absence of other potential causative organisms.
* Anemia
* High IL-10
* High IL-6
* Raised CK
* Raised LDH
* Raised triglycerides
* Raised troponin
* Thrombocytopenia

Radiological Findings"www.rcpch.ac.uk" (PDF).

| *Evaluation of Child for MIS-C.|

|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|

| Stable Child

* Fever(≥ 38.0°C) for ≥ 3 days.

Presence of clinical features|

| Unstable Child(Sepsis)

Fever(≥ 38.0°C) for ≥ 1 day Presence of signs/symptom

* Evidence of myocardial dysfunction or hypotension

| {{{ C01 }}}|

D01|

| D02|

| D03

E01|

| E02|

| E03

| F01|

| F02
Test  | Findings

|

Chest Xray | patchy symmetrical infiltrates, pleural effusion
Echocardiogram and EKG | myocarditis, valvulitis, pericardial effusion, coronary artery dilatation
Abdominal USG | colitis, ileitis, lymphadenopathy, ascites, hepatosplenomegaly

#### Diagnosis

[edit | edit source]

Preliminary WHO case definition: Children and adolescents

* 0–19 years of age with fever >3 days

AND

* Two of the following:

1. Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs (oral, hands or feet)
2. Hypotension or shock
3. Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP)
4. Evidence of coagulopathy (by PT, PTT, elevated D-Dimers)
5. Acute gastrointestinal problems (diarrhea, vomiting, or abdominal pain)

AND

* Elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin

AND

* No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes

AND

* Evidence of COVID-19 (RT-PCR, antigen test or serology-positive), or likely contact with patients with COVID-19

Treatment

* All the children with MIS-C are treated as suspected COVID-19.
* Mild to Moderate cases of MIS-C are managed supportively.
* Anti-inflammatory treatments with Intravenous immunoglobulin(IVIG) with or without corticosteroids have shown a good response rate.[6]
* Aspirin has been used primarily for its antiplatelet effect.[6]
* The antiviral therapy where required are only given in the context of clinical trials(Eg RECOVERY TRIAL).
* Empiric antibiotics like vancomycin, ceftriaxone, and clindamycin are given for community-acquired shock presentation until cultures are negative for 48 hours."www.childrensmn.org" (PDF).
* Fluid resuscitation in 10 ml/kg aliquots with reevaluation after each bolus. Maintain euvolemia. Avoid hypervolemia.

Prevention of MIS-C

* MIS-C can be prevented by reducing the risk of child exposure to COVID-19 infection.

Complications of MIS-C

* Severe myocardial infarction"www.childrensmn.org" (PDF).
* Cardiac failure/arrest
* ARDS
* Fluid Overload
* Acute Kidney Injury
* Peritonitis
* Thrombotic complications.

### Acute Heart Failure

[edit | edit source]

* Acute Cardiac decompensation have been reported in children due to severe inflammatory state following COVID-19 infection. A case series describe 35 children in 14 centers admitted to PICU for cardiogenic shock, left ventricular dysfunction, and severe inflammatory state.[7]

### Complication 2

[edit | edit source]

## COVID-19 and HIV

[edit | edit source]

### Overview

[edit | edit source]

* An observational prospective study found out that the incidence of HIV-infected individuals to be affected by SARS-CoV-2 was similar to the general population.
* Specific antiretroviral therapy did not affect COVID-19 severity.
* Immunosuppression(low CD4 cell counts) was associated with COVID-19 severity.
* Patients with HIV infection often have other comorbidities(lung disease, cardiovascular disease) therefore, increasing the risk for severe-COVID-19 disease.

### Risk

[edit | edit source]

* At present people with HIV who are at greatest risk of Severe COVID-19 infection are people -
* who have lowCD4 cell count.
* not on antiretroviral therapy.

### Presentation

[edit | edit source]

* There hasn't been any observable difference in clinical presentation among people with HIV infection as compared to the general population.
* Common symptoms for COVID-19 are
* Fever or chills
* Cough[8]
* Shortness of Breath or difficulty breathing
* Fatigue
* Muscle or Body aches
* Headache
* New loss of taste or smell
* Sore Throat
* Congestion or runny nose
* Nausea or vomiting
* Diarrhea

### Recommendations for Patients with HIV

[edit | edit source]

* Maintain the supply for antiretroviral therapy for a minimum of 30 days.
* Virtual visit and telemedicine should be considered for non-urgent care and non-adherence counseling
* People with suppressed HIV viral load and in stable health, should postpone their routine medical care and laboratory visits to the extent possible.
* If they develop symptoms of COVID-19 like fever, cough, shortness of breath, etc they should seek medical advice.
* They should make sure their vaccination status is uptodate.

### Specific Populations with HIV

[edit | edit source]

#### Pregnant Patients

[edit | edit source]

* |

| Box 1 in Row 1|

|
|
|
|
|
|

| Box 2 in Row 2|

Box 3 in Row 3|

| Box 4 in Row 4

1. ↑ 1.0 1.1 Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB; et al. (2020). "Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus". World J Pediatr. 16 (3): 240–246. doi:10.1007/s12519-020-00345-5. PMC 7091166 Check `|pmc=` value (help). PMID 32026148 Check `|pmid=` value (help).CS1 maint: Multiple names: authors list (link)
2. ↑ Diotallevi, Federico; Campanati, Anna; Bianchelli, Tommaso; Bobyr, Ivan; Luchetti, Michele Maria; Marconi, Barbara; Martina, Emanuela; Radi, Giulia; Offidani, Annamaria (2020). "Skin involvement in SARS‐CoV‐2 infection: Case series". Journal of Medical Virology. doi:10.1002/jmv.26012. ISSN 0146-6615.
3. ↑ Andina, David; Noguera‐Morel, Lucero; Bascuas‐Arribas, Marta; Gaitero‐Tristán, Jara; Alonso‐Cadenas, José Antonio; Escalada‐Pellitero, Silvia; Hernández‐Martín, Ángela; Torre‐Espi, Mercedes; Colmenero, Isabel; Torrelo, Antonio (2020). "Chilblains in children in the setting of COVID‐19 pandemic". Pediatric Dermatology. 37 (3): 406–411. doi:10.1111/pde.14215. ISSN 0736-8046.
4. ↑ Dugue, Rachelle; Cay-Martínez, Karla C.; Thakur, Kiran T.; Garcia, Joel A.; Chauhan, Lokendra V.; Williams, Simon H.; Briese, Thomas; Jain, Komal; Foca, Marc; McBrian, Danielle K.; Bain, Jennifer M.; Lipkin, W. Ian; Mishra, Nischay (2020). "Neurologic manifestations in an infant with COVID-19". Neurology. 94 (24): 1100–1102. doi:10.1212/WNL.0000000000009653. ISSN 0028-3878.
5. ↑ <https://www.chkd.org/uploadedFiles/Documents/COVID-19/CHKD MIS-C Guideline D2.pdf >
6. ↑ 6.0 6.1 Rajapakse, Nipunie; Dixit, Devika (2020). "Human and novel coronavirus infections in children: a review". Paediatrics and International Child Health: 1–20. doi:10.1080/20469047.2020.1781356. ISSN 2046-9047.
7. ↑ Belhadjer, Zahra; Méot, Mathilde; Bajolle, Fanny; Khraiche, Diala; Legendre, Antoine; Abakka, Samya; Auriau, Johanne; Grimaud, Marion; Oualha, Mehdi; Beghetti, Maurice; Wacker, Julie; Ovaert, Caroline; Hascoet, Sebastien; Selegny, Maëlle; Malekzadeh-Milani, Sophie; Maltret, Alice; Bosser, Gilles; Giroux, Nathan; Bonnemains, Laurent; Bordet, Jeanne; Di Filippo, Sylvie; Mauran, Pierre; Falcon-Eicher, Sylvie; Thambo, Jean-Benoît; Lefort, Bruno; Moceri, Pamela; Houyel, Lucile; Renolleau, Sylvain; Bonnet, Damien (2020). "Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic". Circulation. doi:10.1161/CIRCULATIONAHA.120.048360. ISSN 0009-7322.
8. ↑ <https://www.chkd.org/uploadedFiles/Documents/COVID-19/CHKD MIS-C Guideline D2.pdf >